300347:SZSEHangzhou Tigermed Consulting Co., Ltd. Class A Analysis

Hangzhou Tigermed Consulting is trading at a **trailing P/E of 73.5**, far above the **industry average of 26.2**, and its current price of CNY 52.95 is more than three times the **DCF‑derived fair value of 17.2**, suggesting significant overvaluation. The stock’s **RSI of 32** points to near‑oversold conditions, while the price sits just above the **support level of 52.88**, indicating a potential short‑term bounce. Technical momentum is mixed: the **20‑day SMA (58.68) lies above price**, and the **MACD histogram is negative**, signalling bearish pressure despite the low **beta of 0.14** and a **stable volume trend**. Fundamentals show modest **revenue growth of 3.9%**, solid **gross margin of 26.5%**, but a **high debt‑to‑equity ratio of 7.07**, raising concerns about leverage. The company pays a **0.57% dividend** with a **payout ratio of 41.7%**, which appears sustainable given strong operating cash flow, yet the modest **ROE of 2.6%** limits growth appeal. Recent exposure at the 44th J.P. Morgan Healthcare Conference underscores market interest in its CRO platform, but the combination of lofty valuation multiples, high leverage, and elevated short‑term volatility (≈ 43% over 30 days) suggests caution.